Abstract 640P
Background
The efficacy of checkpoint inhibitor immunotherapy in MSI-H mCRC has not been replicated in MSS mCRC. Therefore, additional interventions are needed to convert immunologically “cold” MSS CRC to “hot” tumors resembling MSI-H tumors. PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine containing 12 immunogenic epitopes derived from 7 cancer testis antigens which demonstrated early evidence of clinical activity, in first-line MSS mCRC.
Methods
Patients with MSS mCRC who have progressed on 2-3 lines of prior chemotherapy regimen received PolyPEPI1018 (1.2 mg, sc) and atezolizumab (1,200 mg, iv) Q3W. The primary endpoint was safety. A Simon 2-stage design was applied; data from the stage 1 of the study will be presented.
Results
18 patients (77% female) were enrolled for stage 1 of the study. At baseline, median age was 55 years (range 38–79), 50% had liver metastases and 61% received at least 3 lines of prior therapies. PD-L1 expression was <1% for 85% of patients. The median number of doses received was 4 (range 2-10). A formal review of safety was performed after the initial 6 participants received 2 cycles of study therapy. The combination was well-tolerated; most common side effect related to treatment was Grade (Gr) 1-2 local skin reaction (n=12). Gr 3 events (n=2) at least possibly related to treatment were nausea and vomiting. There were no Gr 4-5 events or study discontinuation due to treatment AE. The ORR was 0% and the DCR was 68% (n=18). Post-treatment, vaccine-specific T cell responses were detected in the PBMC of 3/4 subjects tested and 3/5 patients had increased density of CD3+ and CD8+ TILs by up to 10-fold. The average PD-L1 expression (IC %) increased significantly after treatment (n=5; p=0.04), consequently 2/5 patients’ tumor converted to high Immunoscore (Veracyte).
Conclusions
PolyPEPI1018 in combination with atezolizumab has a manageable safety profile. PolyPEPI1018 induced immunological responses at both peripheral and tumor level, converted “cold” tumor into “hot”, although to date no responses per RECIST have been noted. The study is on-going.
Clinical trial identification
NCT05243862.
Editorial acknowledgement
Legal entity responsible for the study
Treos Bio Ltd.
Funding
Treos Bio Ltd, Roche.
Disclosure
J. Hubbard: Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Institutional, Advisory Board: Incyte, Bayer, BeiGene; Financial Interests, Institutional, Local PI: Boston Biomedical, Senhwa Biosciences, Bayer, Merck, Hutchison MediPharma, Seattle Genetics, Tovogene, Trioncology, Incyte, Pionyr, G1 Therapeutics, Effector Therapeutics, Roche; Financial Interests, Institutional, Coordinating PI: Taiho Pharmaceutical, TreoBio. M. Kremlitzka: Financial Interests, Personal, Full or part-time Employment, I am an employee of Treos Bio Ltd., working as a Senior Immunologist: Treos Bio Limited. Z. Csiszovszki: Financial Interests, Personal, Full or part-time Employment: Treos Bio Zrt; Financial Interests, Personal, Stocks/Shares: Treos Bio Ltd. E. Somogyi: Financial Interests, Personal, Full or part-time Employment, I am senior researcher at Treos Bio Zrt.: Treos Bio Zrt.; Financial Interests, Personal, Stocks/Shares, I hold shares at Treos Bio Ltd.: Treos Bio Ltd.. O. Lorincz: Financial Interests, Personal, Full or part-time Employment: Treos Bio; Financial Interests, Personal, Stocks/Shares: Treos Bio. L. Molnar: Financial Interests, Personal, Full or part-time Employment: Treos Bio. J. Toth: Financial Interests, Personal, Full or part-time Employment, Bioinformatician: Treos Bio Zrt.; Financial Interests, Personal, Stocks/Shares: Teos Bio Limited. H. Youssoufian: Financial Interests, Personal, Advisory Board: Flamingo, Verastem Oncology, C4 Therapeutics, Treos Bio; Financial Interests, Personal, Ownership Interest: Solid Therapeutics. E.R. Toke: Financial Interests, Personal, Full or part-time Employment: Treos Bio Zrt; Financial Interests, Personal, Member of Board of Directors: Treos Bio Ltd; Financial Interests, Personal, Stocks/Shares: Treos Bio Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11